262 related articles for article (PubMed ID: 19934608)
1. [Diagnosis and treatment guidelines for Helicobacter pylori infection in Korea].
Kim N; Kim JJ; Choe YH; Kim HS; Kim JI; Chung IS; ;
Korean J Gastroenterol; 2009 Nov; 54(5):269-78. PubMed ID: 19934608
[TBL] [Abstract][Full Text] [Related]
2. The Korean perspective of Helicobacter pylori infection: lessons from the Japanese government's policy to prevent gastric cancer.
Park JM; Hahm KB
Dig Dis; 2014; 32(3):290-4. PubMed ID: 24732195
[TBL] [Abstract][Full Text] [Related]
3. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.
Chey WD; Leontiadis GI; Howden CW; Moss SF
Am J Gastroenterol; 2017 Feb; 112(2):212-239. PubMed ID: 28071659
[TBL] [Abstract][Full Text] [Related]
4. Helicobacter pylori: A Review of Current Diagnostic and Management Strategies.
Guevara B; Cogdill AG
Dig Dis Sci; 2020 Jul; 65(7):1917-1931. PubMed ID: 32170476
[TBL] [Abstract][Full Text] [Related]
5. Bismuth-based therapies for the first step eradication of Helicobacter pylori.
Sezgin O; Altintaş E; Uçbilek E; Tataroğlu C
Turk J Gastroenterol; 2006 Jun; 17(2):90-3. PubMed ID: 16830288
[TBL] [Abstract][Full Text] [Related]
6. [Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition].
Kim SG; Jung HK; Lee HL; Jang JY; Lee H; Kim CG; Shin WG; Shin ES; Lee YC;
Korean J Gastroenterol; 2013 Jul; 62(1):3-26. PubMed ID: 23954956
[TBL] [Abstract][Full Text] [Related]
7. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
[TBL] [Abstract][Full Text] [Related]
8. Guidelines in the medical treatment of Helicobacter pylori infection.
Dzieniszewski J; Jarosz M
J Physiol Pharmacol; 2006 Sep; 57 Suppl 3():143-54. PubMed ID: 17033112
[TBL] [Abstract][Full Text] [Related]
9. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability.
Luther J; Higgins PD; Schoenfeld PS; Moayyedi P; Vakil N; Chey WD
Am J Gastroenterol; 2010 Jan; 105(1):65-73. PubMed ID: 19755966
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis and treatment of Helicobacter pylori infection.
Bytzer P; Dahlerup JF; Eriksen JR; Jarbøl DE; Rosenstock S; Wildt S;
Dan Med Bull; 2011 Apr; 58(4):C4271. PubMed ID: 21466771
[TBL] [Abstract][Full Text] [Related]
11. What is the impact of Helicobacter pylori density on the success of eradication therapy: a clinico-histopathological study.
Onal IK; Gokcan H; Benzer E; Bilir G; Oztas E
Clin Res Hepatol Gastroenterol; 2013 Dec; 37(6):642-6. PubMed ID: 23796974
[TBL] [Abstract][Full Text] [Related]
12. Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori.
Laine L; Estrada R; Trujillo M; Emami S
Am J Gastroenterol; 1997 Dec; 92(12):2213-5. PubMed ID: 9399755
[TBL] [Abstract][Full Text] [Related]
13. Helicobacter pylori eradication therapy.
Suzuki H; Nishizawa T; Hibi T
Future Microbiol; 2010 Apr; 5(4):639-48. PubMed ID: 20353303
[TBL] [Abstract][Full Text] [Related]
14. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Liou JM; Fang YJ; Chen CC; Bair MJ; Chang CY; Lee YC; Chen MJ; Chen CC; Tseng CH; Hsu YC; Lee JY; Yang TH; Luo JC; Chang CC; Chen CY; Chen PY; Shun CT; Hsu WF; Hu WH; Chen YN; Sheu BS; Lin JT; Wu JY; El-Omar EM; Wu MS;
Lancet; 2016 Nov; 388(10058):2355-2365. PubMed ID: 27769562
[TBL] [Abstract][Full Text] [Related]
15. Comparative study of Helicobacter pylori eradication rates of concomitant therapy vs modified quadruple therapy comprising proton-pump inhibitor, bismuth, amoxicillin, and metronidazole in Korea.
Choe JW; Jung SW; Kim SY; Hyun JJ; Jung YK; Koo JS; Yim HJ; Lee SW
Helicobacter; 2018 Apr; 23(2):e12466. PubMed ID: 29369454
[TBL] [Abstract][Full Text] [Related]
16. The trends of one-week first-line and second-line eradication therapy for Helicobacter pylori infection in Korea.
Chung JW; Lee GH; Han JH; Jeong JY; Choi KS; Kim DH; Jung KW; Choi KD; Song HJ; Jung HY; Kim JH
Hepatogastroenterology; 2011; 58(105):246-50. PubMed ID: 21510323
[TBL] [Abstract][Full Text] [Related]
17. The impact of bismuth addition to sequential treatment on Helicobacter pylori eradication: A pilot study.
Basyigit S; Kefeli A; Sapmaz F; Yeniova AO; Asilturk Z; Hokkaomeroglu M; Uzman M; Nazligul Y
Bosn J Basic Med Sci; 2015 Oct; 15(4):50-4. PubMed ID: 26614852
[TBL] [Abstract][Full Text] [Related]
18. Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia.
Uygun A; Kadayifci A; Yesilova Z; Safali M; Ilgan S; Karaeren N
Clin Ther; 2008 Mar; 30(3):528-34. PubMed ID: 18405790
[TBL] [Abstract][Full Text] [Related]
19. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.
Malfertheiner P; Megraud F; O'Morain C; Bazzoli F; El-Omar E; Graham D; Hunt R; Rokkas T; Vakil N; Kuipers EJ
Gut; 2007 Jun; 56(6):772-81. PubMed ID: 17170018
[TBL] [Abstract][Full Text] [Related]
20. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
Köksal AS; Parlak E; Filik L; Yolcu OF; Odemiş B; Ulker A; Saşmaz N; Ozden A; Sahin B
J Gastroenterol Hepatol; 2005 Apr; 20(4):637-42. PubMed ID: 15836716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
